Journal
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
Volume 7, Issue 5, Pages 1533-+Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jaip.2018.12.003
Keywords
Polyethylene glycol; PEG; Immediate hypersensitivity; Allergy; Polysorbate
Categories
Funding
- National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute [T32 HL87738]
- NIH/National Institute of General Medical Sciences (NIGMS) [T32 GM007569]
- NIH/National Cancer Institute [CA 142665, CA 21765]
- NIH/NIGMS [GM 115279]
- NIH [1P50GM115305-01, 1R01AI103348-01, 1P30AI110527-01A1]
- National Health and Medical Research Foundation of Australia
- Australian Centre for HIV and Hepatitis Virology Research
Ask authors/readers for more resources
BACKGROUND: The most common immediate hypersensitivity to macrogols is associated with polyethylene glycol (PEG) 3350; however, the epidemiology, mechanisms, and cross-reactivity are poorly understood. Thousands of medications contain either PEGs or structurally similar polysorbates. OBJECTIVE: Our objective was to better understand the mechanism, cross-reactivity, and scope of PEG hypersensitivity. METHODS: Two cases with a past history of immediate hypersensitivity to PEG-containing medications were used to study potential mechanisms and cross-reactivity of immediate reactions to PEG 3350. Skin testing and oral challenges with PEG and polysorbate-containing agents were employed to determine clinical reactivity and cross-reactivity between the 2 allergens. Enzyme-linked immunosorbent assay and electrochemiluminescent immunoassay were used to detect anti-PEG specific IgG and IgE, respectively, using PEGylated protein or PEG alone as antigens in 2 cases and 6 PEG 3350 tolerant controls. We searched US Food and Drug Administration (FDA) adverse event reports for immediate reactions to PEG 3350 to determine the potential scope of this problem in the United States. RESULTS: Skin and provocation testing demonstrated symptomatic reactivity in both cases to PEG 3350 and polysorbate 80. Plasma samples were positive for anti-PEGspecific IgE and IgG antibodies only in cases and binding increased directly proportional to the molecular weight of PEG tested. FDA adverse event reports revealed 53 additional cases of possible PEG 3350 anaphylaxis. CONCLUSIONS: Immediate hypersensitivity to PEG 3350 with cross-reactive polysorbate 80 hypersensitivity may be underrecognized in clinical practice and can be detected with clinical skin testing. Our studies raise the possibility of an IgE-mediated type I hypersensitivity mechanism in some cases. (C) 2018 American Academy of Allergy, Asthma & Immunology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available